Modulation of oxidative stress as an anticancer strategy (original) (raw)

• Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nature Rev. Cancer 11, 85–95 (2011).
  Article CAS Google Scholar
• Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009). This paper demonstrates that the mechanism by which cancer stem cells survive radiation (while the remaining tumour is eradicated) is through increased antioxidants and lower ROS levels.
  Article CAS PubMed PubMed Central Google Scholar
• Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077–3080 (2008).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Jones, R. G. & Thompson, C. B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23, 537–548 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Finkel, T. Signal transduction by mitochondrial oxidants. J. Biol. Chem. 287, 4434–4440 (2012).
  Article CAS PubMed Google Scholar
• Handy, D. E. & Loscalzo, J. Redox regulation of mitochondrial function. Antioxid. Redox Signal. 16, 1323–1367 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Schrader, M. & Fahimi, H. D. Peroxisomes and oxidative stress. Biochim. Biophys. Acta 1763, 1755–1766 (2006).
  Article CAS PubMed Google Scholar
• Malhotra, J. D. & Kaufman, R. J. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid. Redox Signal. 9, 2277–2293 (2007).
  Article CAS PubMed Google Scholar
• Sena, L. A. & Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48, 158–167 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Janssen-Heininger, Y. M. et al. Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic. Biol. Med. 45, 1–17 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Rhee, S. G. H2O2, a necessary evil for cell signaling. Science 312, 1882–1883 (2006).
  Article PubMed Google Scholar
• Naik, E. & Dixit, V. M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J. Exp. Med. 208, 417–420 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Gloire, G., Legrand-Poels, S. & Piette, J. NF-κB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72, 1493–1505 (2006).
  Article CAS PubMed Google Scholar
• Oberley, L. W. Free radicals and diabetes. Free Radic. Biol. Med. 5, 113–124 (1988).
  Article CAS PubMed Google Scholar
• Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Rev. Drug Discov. 8, 579–591 (2009).
  Article CAS Google Scholar
• Ranjan, P. et al. Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. Antioxid. Redox Signal. 8, 1447–1459 (2006).
  Article CAS PubMed Google Scholar
• Martindale, J. L. & Holbrook, N. J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192, 1–15 (2002).
  Article CAS PubMed Google Scholar
• Leslie, N. R. et al. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 22, 5501–5510 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, D., Rovira, I. I. & Finkel, T. Oxidants painting the cysteine chapel: redox regulation of PTPs. Dev. Cell 2, 251–252 (2002).
  Article CAS PubMed Google Scholar
• Harris, I. S. et al. PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling. Oncogene http://dx.doi.org/10.1038/onc.2013.24 (2013).
• Shi, X., Zhang, Y., Zheng, J. & Pan, J. Reactive oxygen species in cancer stem cells. Antioxid. Redox Signal. 16, 1215–1228 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, H. M. et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann. Surg. Oncol. 19 (Suppl. 3), 539–548 (2012).
  Article Google Scholar
• Schafer, Z. T. et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109–113 (2009). This study reported that, upon matrix detachment, cancer cells undergo an increase in ROS levels, which can be alleviated by oncogene expression.
  Article CAS PubMed PubMed Central Google Scholar
• Sporn, M. B. & Liby, K. T. NRF2 and cancer: the good, the bad and the importance of context. Nature Rev. Cancer 12, 564–571 (2012).
  Article CAS Google Scholar
• Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16, 123–140 (2011).
  Article CAS PubMed Google Scholar
• Meister, A. Selective modification of glutathione metabolism. Science 220, 472–477 (1983).
  Article CAS PubMed Google Scholar
• Sasaki, H. et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277, 44765–44771 (2002).
  Article CAS PubMed Google Scholar
• Mandal, P. K. et al. System x(c)- and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J. Biol. Chem. 285, 22244–22253 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Johansson, L., Gafvelin, G. & Arner, E. S. Selenocysteine in proteins — properties and biotechnological use. Biochim. Biophys. Acta 1726, 1–13 (2005).
  Article CAS PubMed Google Scholar
• Zhang, W. et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature Cell Biol. 14, 276–286 (2012). This paper identifies the functional role of CD44 in increasing cystine uptake and lowering ROS levels.
  Article CAS PubMed Google Scholar
• Ishimoto, T. et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc− and thereby promotes tumor growth. Cancer Cell 19, 387–400 (2011).
  Article CAS PubMed Google Scholar
• McGrath-Morrow, S. et al. Nrf2 increases survival and attenuates alveolar growth inhibition in neonatal mice exposed to hyperoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L565–L573 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Thimmulappa, R. K. et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196–5203 (2002).
  CAS PubMed Google Scholar
• Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
  CAS PubMed PubMed Central Google Scholar
• Mitsuishi, Y. et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66–79 (2012).
  Article CAS PubMed Google Scholar
• Arner, E. S. & Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109 (2000).
  Article CAS PubMed Google Scholar
• Chorley, B. N. et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 40, 7416–7429 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, Y. J. et al. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 67, 546–554 (2007).
  Article CAS PubMed Google Scholar
• Gutteridge, J. M. Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides. FEBS Lett. 201, 291–295 (1986).
  Article CAS PubMed Google Scholar
• Gozzelino, R., Jeney, V. & Soares, M. P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 50, 323–354 (2010).
  Article CAS PubMed Google Scholar
• Alam, J. et al. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 274, 26071–26078 (1999).
  Article CAS PubMed Google Scholar
• Orino, K. et al. Ferritin and the response to oxidative stress. Biochem. J. 357, 241–247 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Weinberg, E. D. The role of iron in cancer. Eur. J. Cancer Prev. 5, 19–36 (1996).
  CAS PubMed Google Scholar
• Kops, G. J. et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630–634 (1999).
  Article CAS PubMed Google Scholar
• Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857–868 (1999).
  Article CAS PubMed Google Scholar
• Brunet, A. et al. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21, 952–965 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Greer, E. L. & Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410–7425 (2005).
  Article CAS PubMed Google Scholar
• Essers, M. A. et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 23, 4802–4812 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Lehtinen, M. K. et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125, 987–1001 (2006).
  Article CAS PubMed Google Scholar
• Nemoto, S. & Finkel, T. Redox regulation of forkhead proteins through a _p66shc_-dependent signaling pathway. Science 295, 2450–2452 (2002).
  Article CAS PubMed Google Scholar
• Yalcin, S. et al. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J. Biol. Chem. 283, 25692–25705 (2008).
  Article CAS PubMed Google Scholar
• Greer, E. L. et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 282, 30107–30119 (2007).
  Article CAS PubMed Google Scholar
• Cheng, Z. et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nature Med. 15, 1307–1311 (2009).
  Article CAS PubMed Google Scholar
• Mei, Y. et al. FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. Proc. Natl Acad. Sci. USA 106, 5153–5158 (2009).
  Article PubMed PubMed Central Google Scholar
• Martin, S. A., Hewish, M., Sims, D., Lord, C. J. & Ashworth, A. Parallel high throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair deficient cancers. Cancer Res. 71, 1836–1848 (2011).
  Article CAS PubMed Google Scholar
• Nogueira, V. et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14, 458–470 (2008). This paper reports the discovery that hyperactivation of the PI3K–AKT pathway can sensitize cancer cells to oxidative stress owing to the inactivation of FOXO factors and the resulting decrease in the expression of antioxidant enzymes.
  Article CAS PubMed PubMed Central Google Scholar
• Kops, G. J. et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316–321 (2002).
  Article CAS PubMed Google Scholar
• Woo, H. A., Bae, S. H., Park, S. & Rhee, S. G. Sestrin 2 is not a reductase for cysteine sulfinic acid of peroxiredoxins. Antioxid. Redox Signal. 11, 739–745 (2009).
  Article CAS PubMed Google Scholar
• Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nature Rev. Cancer 9, 691–700 (2009).
  Article CAS Google Scholar
• Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120 (2006). This paper identifies the role of the novel p53 gene TIGAR , which supports NADPH production by diverting metabolites into the PPP.
  Article CAS PubMed Google Scholar
• Suzuki, S. et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl Acad. Sci. USA 107, 7461–7466 (2010).
  Article PubMed PubMed Central Google Scholar
• Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762–765 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, W. et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol. Cell 34, 663–673 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211–223 (2004).
  Article CAS PubMed Google Scholar
• Meiller, A. et al. p53-dependent stimulation of redox-related genes in the lymphoid organs of γ-irradiated mice — identification of haeme-oxygenase 1 as a direct p53 target gene. Nucleic Acids Res. 35, 6924–6934 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Pinnix, Z. K. et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2, 43ra56 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hayes, J. D., McMahon, M., Chowdhry, S. & Dinkova-Kostova, A. T. Cancer chemoprevention mechanisms mediated through the Keap1–Nrf2 pathway. Antioxid. Redox Signal. 13, 1713–1748 (2010).
  Article CAS PubMed Google Scholar
• Hu, R., Saw, C. L., Yu, R. & Kong, A. N. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid. Redox Signal. 13, 1679–1698 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225–228 (2011).
  Article CAS PubMed Google Scholar
• DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109 (2011). This study shows that the physiological expression of oncogenes can lead to decreased ROS levels through NRF2 antioxidant transcription.
  Article CAS PubMed PubMed Central Google Scholar
• Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W. & Ting, J. P. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl Acad. Sci. USA 103, 15091–15096 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, R. H. et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7, 263–273 (2005).
  Article CAS PubMed Google Scholar
• Vasseur, S. et al. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc. Natl Acad. Sci. USA 106, 1111–1116 (2009).
  Article PubMed PubMed Central Google Scholar
• Vasseur, S. et al. Consequences of DJ-1 upregulation following p53 loss and cell transformation. Oncogene 31, 664–670 (2012).
  Article CAS PubMed Google Scholar
• Lee, J. & Wolfgang, M. J. Metabolomic profiling reveals a role for CPT1c in neuronal oxidative metabolism. BMC Biochem. 13, 23 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Zaugg, K. et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25, 1041–1051 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sanchez-Macedo, N. et al. Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ. 20, 659–668 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, Y. R. et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 220, 446–451 (2010).
  Article CAS PubMed Google Scholar
• Shibata, T. et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl Acad. Sci. USA 105, 13568–13573 (2008).
  Article PubMed PubMed Central Google Scholar
• Hayes, J. D. & McMahon, M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34, 176–188 (2009).
  Article CAS PubMed Google Scholar
• Tenbaum, S. P. et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature Med. 18, 892–901 (2012).
  Article CAS PubMed Google Scholar
• Naka, K. et al. TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463, 676–680 (2010).
  Article CAS PubMed Google Scholar
• Sykes, S. M. et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146, 697–708 (2011).
  Article CAS PubMed Google Scholar
• Burgering, B. M. & Medema, R. H. Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J. Leukoc. Biol. 73, 689–701 (2003).
  Article CAS PubMed Google Scholar
• Olanich, M. E. & Barr, F. G. A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma. Expert Opin. Ther. Targets 17, 607–623 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• del Peso, L., Gonzalez, V. M., Hernandez, R., Barr, F. G. & Nunez, G. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18, 7328–7333 (1999).
  Article CAS PubMed Google Scholar
• Li, B., Gordon, G. M., Du, C. H., Xu, J. & Du, W. Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell 17, 469–480 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jeon, S. M., Chandel, N. S. & Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485, 661–665 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bae, I. et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 64, 7893–7909 (2004).
  Article CAS PubMed Google Scholar
• Saha, T., Rih, J. K. & Rosen, E. M. BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett. 583, 1535–1543 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Gorrini, C. et al. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J. Exp. Med. 210, 1529–1544 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Barzilai, A., Rotman, G. & Shiloh, Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair 1, 3–25 (2002).
  Article CAS PubMed Google Scholar
• Ito, K. et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431, 997–1002 (2004).
  Article CAS PubMed Google Scholar
• Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D. & Paull, T. T. ATM activation by oxidative stress. Science. 330, 517–521 (2010).
  Article CAS PubMed Google Scholar
• Alexander, A. et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl Acad. Sci. USA 107, 4153–4158 (2010).
  Article PubMed PubMed Central Google Scholar
• Adam, J. et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524–537 (2011). This paper demonstrates that NRF2 is stabilized upon loss of the tumour suppressor gene fumarate hydratase.
  Article CAS PubMed PubMed Central Google Scholar
• Ooi, A. et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20, 511–523 (2011).
  Article CAS PubMed Google Scholar
• Sullivan, L. B. et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 51, 236–248 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Mazurek, S., Boschek, C. B., Hugo, F. & Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15, 300–308 (2005).
  Article CAS PubMed Google Scholar
• Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 (2008).
  Article CAS PubMed Google Scholar
• Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181–186 (2008).
  Article CAS PubMed Google Scholar
• Vander Heiden, M. G. et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492–1499 (2010).
  Article CAS PubMed Google Scholar
• Anastasiou, D. et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to antioxidant responses. Science 334, 1278–1283 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Locasale, J. W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genet. 43, 869–874 (2011).
  Article CAS PubMed Google Scholar
• Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040–1044 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chaneton, B. et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458–462 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Goodison, S., Urquidi, V. & Tarin, D. CD44 cell adhesion molecules. Mol. Pathol. 52, 189–196 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Zoller, M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nature Rev. Cancer 11, 254–267 (2011).
  Article CAS Google Scholar
• Blot, W. J. et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl Cancer Inst. 85, 1483–1492 (1993).
  Article CAS PubMed Google Scholar
• Qiao, Y. L. et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J. Natl Cancer Inst. 101, 507–518 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, W. et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J. Natl Cancer Inst. 104, 1173–1181 (2012).
  Article CAS PubMed Google Scholar
• Hurst, R. et al. Selenium and prostate cancer: systematic review and meta-analysis. Am. J. Clin. Nutr. 96, 111–122 (2012).
  Article CAS PubMed Google Scholar
• Richman, E. L. & Chan, J. M. Selenium and prostate cancer: the puzzle isn't finished yet. Am. J. Clin. Nutr. 96, 1–2 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Klein, E. A. et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549–1556 (2011). This was the first large study on the link between vitamin E supplementation and cancer risk, in contrast to early observations suggesting that vitamin E has a protective effect against cancer.
  Article CAS PubMed PubMed Central Google Scholar
• Su, Z. Y. et al. A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, Nrf2, and epigenomics. Top. Curr. Chem. 329, 133–162 (2012).
  Article CAS Google Scholar
• Kim, Y. S., Farrar, W., Colburn, N. H. & Milner, J. A. Cancer stem cells: potential target for bioactive food components. J. Nutrit. Biochem. 23, 691–698 (2012).
  Article CAS Google Scholar
• Conklin, K. A. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 3, 294–300 (2004).
  Article CAS PubMed Google Scholar
• Barrera, G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012, 137289 (2012).
  PubMed PubMed Central Google Scholar
• Santiago-Arteche, R. et al. Cancer chemotherapy reduces plasma total polyphenols and total antioxidants capacity in colorectal cancer patients. Mol. Biol. Rep. 39, 9355–9360 (2012).
  Article CAS PubMed Google Scholar
• Kaufmann, S. H. & Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256, 42–49 (2000).
  Article CAS PubMed Google Scholar
• Miller, W. H. et al. Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893–3903 (2002).
  CAS PubMed Google Scholar
• Yi, J. et al. The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 7, 209–215 (2002).
  Article CAS PubMed Google Scholar
• Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev. Cancer 3, 330–338 (2003).
  Article CAS Google Scholar
• Hwang, P. M. et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nature Med. 7, 1111–1117 (2001).
  Article CAS PubMed Google Scholar
• Hwang, I. T. et al. Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem. Biophys. Res. Commun. 359, 304–310 (2007).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells. Cancer Lett. 313, 201–210 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kachadourian, R. et al. 2-methoxyestradiol does not inhibit superoxide dismutase. Arch. Biochem. Biophys. 392, 349–353 (2001).
  Article CAS PubMed Google Scholar
• Lai, W. L. & Wong, N. S. ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene. Free Radic. Biol. Med. 38, 1585–1593 (2005).
  Article CAS PubMed Google Scholar
• Apraiz, A. et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochem. Cell Biol. 90, 209–223 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Neckers, L. & Workman, P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18, 64–76 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hao, H. et al. HSP90 and its inhibitors. Oncol. Rep. 23, 1483–1492 (2010).
  CAS PubMed Google Scholar
• Scarbrough, P. M. et al. Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic. Biol. Med. 52, 436–443 (2012).
  Article CAS PubMed Google Scholar
• De Raedt, T. et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors. Cancer Cell 20, 400–413 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Metzger-Filho, O. et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30, 1879–1887 (2012).
  Article CAS PubMed Google Scholar
• Masaoka, A., Horton, J. K., Beard, W. A. & Wilson, S. H. DNA polymerase beta and PARP activities in base excision repair in living cells. DNA Repair 8, 1290–1299 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, X. & Kraus, W. L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 26, 417–432 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Berndtsson, M. et al. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer 120, 175–180 (2007).
  Article CAS PubMed Google Scholar
• Kummar, S. et al. Advances in using PARP inhibitors to treat cancer. BMC Med. 10, 25 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079–17084 (2008). The discovery of PARP inhibitors have brought hope in the treatment of BRCA1-mutated cancers. This work shows the efficacy of PARP inhibitors in combination with platinum drugs.
  Article PubMed PubMed Central Google Scholar
• Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916–3925 (2008).
  Article CAS PubMed Google Scholar
• Michels, J. et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 73, 2271–2280 (2013).
  Article CAS PubMed Google Scholar
• Michels, J. et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 12, 877–883 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Yoshida, T., Goto, S., Kawakatsu, M., Urata, Y. & Li, T. S. Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation. Free Radic. Res. 46, 147–153 (2012).
  Article CAS PubMed Google Scholar
• Wang, Y. et al. Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Radic. Biol. Med. 48, 348–356 (2010).
  Article CAS PubMed Google Scholar
• Voorhees, P. M., Dees, E. C., O'Neil, B. & Orlowski, R. Z. The proteasome as a target for cancer therapy. Clin. Cancer Res. 9, 6316–6325 (2003).
  CAS PubMed Google Scholar
• Joazeiro, C. A., Anderson, K. C. & Hunter, T. Proteasome inhibitor drugs on the rise. Cancer Res. 66, 7840–7842 (2006).
  Article CAS PubMed Google Scholar
• Papa, L., Gomes, E. & Rockwell, P. Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis 12, 1389–1405 (2007).
  Article CAS PubMed Google Scholar
• Chen, Z. et al. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLoS ONE 8, e69126 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kane, R. C. et al. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 13, 5291–5294 (2007).
  Article CAS PubMed Google Scholar
• Denmeade, S. R. et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci. Transl. Med. 4, 140ra86 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kardosh, A. et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res. 68, 843–851 (2008).
  Article CAS PubMed Google Scholar
• Fribley, A., Zeng, Q. & Wang, C. Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 24, 9695–9704 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Tsutsumi, S. et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ. 11, 1009–1016 (2004).
  Article CAS PubMed Google Scholar
• Bernstein, W. B. & Dennis, P. A. Repositioning HIV protease inhibitors as cancer therapeutics. Curr. Opin. HIV AIDS 3, 666–675 (2008).
  Article PubMed PubMed Central Google Scholar
• Tai, D. J. et al. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp. Ther. Med. 4, 291–296 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ryu, C. S. et al. Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem. Pharmacol. 85, 197–206 (2012).
  Article CAS PubMed Google Scholar
• Griffith, O. W. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem. 257, 13704–13712 (1982).
  CAS PubMed Google Scholar
• Loganathan, S., Kandala, P. K., Gupta, P. & Srivastava, S. K. Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS ONE 7, e43577 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10, 241–252 (2006).
  Article CAS PubMed Google Scholar
• Raj, L. et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231–234 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Suarez-Almazor, M. E., Belseck, E., Shea, B., Wells, G. & Tugwell, P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev. 2009, CD000958 (2000).
  Google Scholar
• Gout, P. W., Buckley, A. R., Simms, C. R. & Bruchovsky, N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15, 1633–1640 (2001).
  Article CAS PubMed Google Scholar
• Lo, M., Ling, V., Low, C., Wang, Y. Z. & Gout, P. W. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr. Oncol. 17, 9–16 (2010).
  CAS PubMed PubMed Central Google Scholar
• Guan, J. et al. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother. Pharmacol. 64, 463–472 (2009).
  Article CAS PubMed Google Scholar
• Montero, A. J. et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res. Treat. 132, 215–223 (2012).
  Article CAS PubMed Google Scholar
• Townsend, D. M. et al. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res. 68, 2870–2877 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sobhakumari, A. et al. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS ONE 7, e48175 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Marzano, C. et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42, 872–881 (2007).
  Article CAS PubMed Google Scholar
• Vaughn, A. E. & Deshmukh, M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nature Cell Biol. 10, 1477–1483 (2008).
  Article CAS PubMed Google Scholar
• Polimeni, M. et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem. J. 439, 141–149 (2011).
  Article CAS PubMed Google Scholar
• Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, J. B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207–219 (2010). This work underlines the importance of metabolic adaptation in cancer cells. It demonstrates that glutamine metabolism is crucial for cancer cell survival.
  Article CAS PubMed PubMed Central Google Scholar
• Le, A. et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell. Metab. 15, 110–121 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Reinert, R. B. et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to l-asparaginase. J. Biol. Chem. 281, 31222–31233 (2006).
  Article CAS PubMed Google Scholar
• Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285–296 (2003). This work demonstrates the potential of tailored therapeutic intervention against specific gene alterations in tumour cells.
  Article CAS PubMed Google Scholar
• Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012). This paper describes a new form of cell death that depends on iron.
  Article CAS PubMed PubMed Central Google Scholar
• Yagoda, N. et al. RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864–868 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Shaw, A. T. et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl Acad. Sci. USA 108, 8773–8778 (2011).
  Article PubMed PubMed Central Google Scholar
• Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009). This study elucidates the presence of a novel metabolic pathway induced by a tumour-specific gene alteration. The finding offers the opportunity to develop a tailored anticancer therapy.
  Article CAS PubMed PubMed Central Google Scholar
• Sasaki, M. et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 26, 2038–2049 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656–659 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
  Article CAS PubMed Google Scholar
• Greenlee, H., Hershman, D. L. & Jacobson, J. S. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res. Treat. 115, 437–452 (2009).
  Article CAS PubMed Google Scholar
• Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Bell, E. L. & Chandel, N. S. Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 43, 17–27 (2007).
  Article CAS PubMed Google Scholar
• Chandel, N. S. et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl Acad. Sci. USA 95, 11715–11720 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Semenza, G. L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365, 537–547 (2011).
  Article CAS PubMed Google Scholar
• Kincaid, M. M. & Cooper, A. A. ERADicate ER stress or die trying. Antioxid. Redox Signal. 9, 2373–2387 (2007).
  Article CAS PubMed Google Scholar
• Bravo, R. et al. Endoplasmic reticulum: ER stress regulates mitochondrial bioenergetics. Int. J. Biochem. Cell Biol. 44, 16–20 (2012).
  Article CAS PubMed Google Scholar
• Tanaka, H. et al. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9, 1017–1029 (2002).
  Article CAS PubMed Google Scholar
• Irani, K. et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275, 1649–1652 (1997).
  Article CAS PubMed Google Scholar
• Lee, A. C. et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J. Biol. Chem. 274, 7936–7940 (1999).
  Article CAS PubMed Google Scholar
• Vafa, O. et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 9, 1031–1044 (2002).
  Article CAS PubMed Google Scholar
• Li, W. & Kong, A. N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 48, 91–104 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51, 155–194 (1991).
  Article CAS PubMed Google Scholar
• Murphy, M. P. Mitochondrial thiols in antioxidant protection and redox signaling: distinct roles for glutathionylation and other thiol modifications. Antioxid. Redox Signal. 16, 476–495 (2012).
  Article CAS PubMed Google Scholar
• Vurusaner, B., Poli, G. & Basaga, H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic. Biol. Med. 52, 7–18 (2012).
  Article CAS PubMed Google Scholar
• Bouayed, J. & Bohn, T. Exogenous antioxidants — double-edged swords in cellular redox state: health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid. Med. Cell Longev. 3, 228–237 (2010).
  Article PubMed PubMed Central Google Scholar
• Wilson, J. X. Regulation of vitamin C transport. Annu. Rev. Nutr. 25, 105–125 (2005).
  Article CAS PubMed Google Scholar
• Brigelius-Flohe, R. & Traber, M. G. Vitamin E: function and metabolism. FASEB J. 13, 1145–1155 (1999).
  Article CAS PubMed Google Scholar
• Rayman, M. P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc. Nutr. Soc. 64, 527–542 (2005).
  Article CAS PubMed Google Scholar
• Burton, G. W. & Ingold, K. U. β-carotene: an unusual type of lipid antioxidant. Science 224, 569–573 (1984).
  Article CAS PubMed Google Scholar
• Klaunig, J. E. & Kamendulis, L. M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 44, 239–267 (2004).
  Article CAS PubMed Google Scholar
• Belfi, C. A., Chatterjee, S., Gosky, D. M., Berger, S. J. & Berger, N. A. Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation. Biochem. Biophys. Res. Commun. 257, 361–368 (1999).
  Article CAS PubMed Google Scholar
• Dufour, E. et al. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas 41, 940–948 (2012).
  Article CAS PubMed Google Scholar
• Pieters, R. et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 117, 238–249 (2011).
  Article CAS PubMed Google Scholar
• O'Dwyer, P. J. et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 14, 249–256 (1996).
  Article CAS PubMed Google Scholar
• Lewis-Wambi, J. S. et al. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Breast Cancer Res. 10, R104 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, J. et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl Cancer Inst. 94, 1745–1757 (2002).
  Article CAS PubMed Google Scholar
• Gills, J. J. et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13, 5183–5194 (2007).
  Article CAS PubMed Google Scholar
• Simunek, T. et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61, 154–171 (2009).
  Article CAS PubMed Google Scholar
• The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330, 1029–1035 (1994).
• Omenn, G. S. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150–1155 (1996).
  Article CAS PubMed Google Scholar
• Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).
  Article CAS PubMed Google Scholar